Načítá se...
Mass spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: Comparison to IHC and FISH
BACKGROUND: Trastuzumab showed survival benefit for Her2-positive gastroesophageal cancers (GEC). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) currently determine eligibility for trastuzumab-based therapy. However, these low-throughput assays often produce discordant or e...
Uloženo v:
Vydáno v: | Gastric Cancer |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
2015
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4871781/ https://ncbi.nlm.nih.gov/pubmed/26581548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-015-0566-0 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|